SynthesisClinical transplantation2026
Hypothermic Oxygenated Perfusion Versus Static Cold Storage in Liver Transplantation: A Meta- Analysis of Randomized Trials.
Synthesis in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypothermic oxygenated machine perfusion (HOPE) is an alternative to static cold storage (SCS) for liver graft preservation, aiming to reduce ischemia-reperfusion injury (IRI) and improve post-transplant outcomes.
methodsWe systematically reviewed randomized controlled trials (RCTs) comparing HOPE with SCS in adult liver transplantation (MEDLINE, EMBASE, CENTRAL to July 2026). Outcomes included early allograft dysfunction (EAD), primary non-function (PNF), major postoperative complications, biliary complications, including non-anastomotic strictures (NAS), graft survival, and retransplantation.
resultsEight RCTs (984 patients; HOPE 461; SCS 523) met inclusion criteria. HOPE significantly reduced EAD (17.8% vs. 33.5%; RR 0.54, 95% CI 0.43-0.68; p < 0.00001) and PNF (0.4% vs. 3.6%; RR 0.26, 95% CI 0.09-0.75; p = 0.01). HOPE was associated with fewer major complications (Clavien-Dindo ≥ III) (41.2% vs. 50.7%; RR 0.80, 95% CI 0.70-0.93; p = 0.003), lower overall biliary complications (18.9% vs. 27.7%; RR 0.72, 95% CI 0.58-0.90; p = 0.004) and reduced NAS (3.3% vs. 7.6%; RR 0.43, 95% CI 0.23-0.82; p = 0.01). One-year graft survival was comparable, while retransplantation was reduced after HOPE (RR 0.35, 95% CI 0.14-0.84, p = 0.02).
conclusionHOPE improves early graft outcomes and reduces biliary morbidity and retransplantation compared with SCS, supporting its use to mitigate IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.